NF-kappaB (NFkB): Target of Many Drugs for Disease Treatment (P6058)

Target Name: NF-kappaB (NFkB)

NCBI ID: P6058

NF-kappaB (NFkB)

Other Name(s): NFKB | Nuclear Factor-kappaB | NFkB

NF-kappaB (NFkB): Target of Many Drugs for Disease Treatment

NF-kappa-B (NFKB) is a protein that plays a crucial role in regulating various cellular processes in the body. It is a transcription factor that is involved in the regulation of gene expression, cell signaling, and inflammation. NF-kappa-B has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it has become a focus of intense research in the pharmaceutical industry, with many drugs currently in development targeting NF-kappa-B.

The NFKB pathway is involved in the regulation of gene expression by binding to specific DNA sequences. This pathway is activated by various factors, including double stress, UV radiation, and certain medications. Once NF-kappa-B is activated, it can induce the expression of target genes that are involved in a wide range of cellular processes, including inflammation, stress response, and cell survival.

One of the key targets of NF-kappa-B is the transcription factor AP-1. AP-1 is a transcription factor that can bind to the DNA binding site of NF-kappa-B, thereby promoting the activation of NF-kappa-B. Activation of AP-1 can lead to increased expression of a variety of genes, including inflammatory genes, cell cycle genes, and cell growth factors. In addition, the activation of AP-1 can also induce a series of signaling pathways, including the PI3K/A2P signaling pathway and the NF-kappa-B signaling pathway, thereby further regulating intracellular signal transmission.

NF-kappa-B is also involved in regulating the differentiation and function of immune cells. In the inflammatory response, NF-kappa-B can promote the activation and proliferation of immune cells, thus aggravating inflammatory symptoms. In addition, NF-kappa-B can also inhibit the apoptosis of immune cells, thereby protecting immune cells from harmful stimuli. These effects enable NF-kappa-B to play an important role in the immune system.

Due to its important role in many diseases, NF-kappa-B has become the target of many drug studies. Currently, there are many drugs under development aimed at inhibiting the activity of NF-kappa-B to treat various diseases. Some of these drugs have been approved for the treatment of various tumors and neurological diseases. In addition, some drugs are undergoing clinical studies to evaluate their effects on NF-kappa-B activity.

Although the role of NF-kappa-B in the treatment of various diseases has received extensive research and attention, there are still many challenges that need to be overcome. For example, many NF-kappa-B inhibitors are affected by multiple regulatory mechanisms in vivo, resulting in their reduced bioavailability. In addition, NF-kappa-B is closely related to the occurrence and development of various diseases, so more in-depth research on the biological mechanism of NF-kappa-B is needed.

NF-kappa-B is an important protein that plays an important role in the onset and development of many diseases. Currently, there are many drugs under development aimed at inhibiting the activity of NF-kappa-B to treat various diseases. With the deepening of research, NF-kappa-B may also become a potential target for the treatment of various diseases in the future.

Protein Name: NF-kappaB (NFkB)

The "NF-kappaB (NFkB) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NF-kappaB (NFkB) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets